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Abstract
Background: Paraoxonase-1 (PON1), a lactonase synthesized by the liver, circulates in blood bound to high-density 
lipoproteins (HDL). This enzyme is thought to degrade oxidized phospholipids and play an important role in the 
organism's antioxidant and anti-inflammatory system. Chronic liver diseases are characterized by decreased serum 
PON1 activity. The aim of the present study was to investigate the compositional changes in HDL that could influence 
PON1 activity in liver impairment.
Methods: The study was performed in samples from five patients with advanced liver cirrhosis and with preserved 
renal function, chosen on the basis of having low serum PON1 activity and high serum PON1 concentration. As a 
control group, we accessed five healthy volunteers from among our hospital staff. Lipid and protein compositional 
analysis of lipoprotein particles were done by high-performance liquid chromatography, gel electrophoresis, and 
Western-Blot.
Results: HDL particles from cirrhotic patients had an increased phospholipid content that was inversely correlated to 
PON1 activity. The HDL particles contained high levels of PON1 that corresponded, in part, to an immunoreactive 
protein of high molecular weight (55 kDa) not present in control subjects. This protein was identified as glycosylated 
PON1 and was also present in biopsies from patients with steatosis and from rats with CCl4-induced hepatic 
impairment. These changes were associated with an increased plasma concentration of markers of oxidative stress, 
inflammation and fibrogenesis.
Conclusion: Abnormalities in the composition of lipids and proteins of HDL particles, including PON1 glycosylation, 
are associated with the decrease in serum PON1 activity in patients with liver disease. These alterations may adversely 
affect the protective role of HDL against oxidative stress and inflammation in these patients.
Background
Paraoxonase-1 (PON1) is an esterase and lactonase that is
found in the circulation bound to high-density lipopro-
teins (HDL) [1]. The original function of PON1 was that
of a lactonase; lipophylic lactones constituting its primary
substrates [2]. PON1 is thought to degrade oxidized
phospholipids in lipoproteins and play an important role
in the organism's antioxidant system [3,4]. Alterations in
circulating PON1 levels have been found associated with
a variety of diseases involving oxidative stress [5,6].
Experimental data show a clear link between PON1,
HDL and inflammation. HDL particles possess anti-
inflammatory properties, including the suppression of
cytokine-induced endothelial cell adhesion molecules
[7,8]. Recent studies in healthy volunteers showed a close
relationship between circulating HDL levels and the
inflammatory response to endotoxin challenge; the inci-
dence and severity of clinical symptoms and the plasma
concentrations of tumor necrosis factor, interleukins 1, 6
and 8, and monocyte chemoattractant protein-1 (MCP-1)
being higher in subjects with low HDL than in those with
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normal HDL levels [9]. MCP-1 is intimately involved in
the inflammatory reaction. This chemokine regulates the
migration of monocytes into tissues and their subsequent
differentiation into macrophages [10]. An end-product of
lipid peroxidation (4-hydroxy-2-nonenal) and oxidized
phospholipids present in LDL have been shown to stimu-
late the production of MCP-1 in vitro [11-13]. We had
demonstrated that PON1 inhibits MCP-1 production in
endothelial cells incubated with oxidized LDL, and that
this property appeared to be due to its capacity to inhibit
LDL oxidation [14]. Studies in experimental animals sup-
port the concept of an anti-inflammatory role for PON1.
Transgenic mice fed a high-fat and high-cholesterol diet
developed less atherosclerotic lesions, lower oxidative
stress, and lower MCP-1 expression in their aortas than
their corresponding control littermates [15]. These
results confirm other studies that had shown that PON1
knock-out mice had higher peripheral lipid peroxidation
and a higher degree of macrophage oxidative stress [16].
Further, a recent study showed that, even in the absence
of hyperlipidemia, PON1 deficiency promoted pro-
inflammatory changes in the expression of adhesins [17].
The liver plays a key role in the synthesis of PON1 [18],
and chronic liver diseases are associated with increased
oxidative stress, MCP-1 synthesis, and inflammation
[19,20]. In previous studies, we reported that serum
PON1 activity is decreased in patients with chronic liver
impairment, while serum PON1 concentration and
hepatic PON1 protein expression are increased [21-23].
More recent evidence indicates that PON1 over-expres-
sion provides strong protection against the development
of experimental liver disease [24]. Conversely, low PON1
activity is associated with an enhanced sensitivity to the
development of liver damage [25].
Not much is known about the biochemical mechanisms
underlying these alterations in PON1 synthesis and
secretion in liver diseases. A likely hypothesis is that
PON1 activity is influenced by alterations in HDL struc-
ture and composition, secondary to an impaired synthesis
of this lipoprotein by the liver. This subject has not been
sufficiently explored, to-date. We performed the present
study to investigate the lipid and protein changes in HDL
particles that could potentially influence PON1 activity
and, as well, the effect of these changes on oxidative stress
and inflammation in patients with chronic liver impair-
ment.
Methods
Participants
As stated before, case-control studies showing a
decreased serum PON1 activity and increased PON1
concentration have already been published [21-23], and
the aim of the present investigation was to add a further
insight into the hypothesis that these changes may be
related to other HDL compositional alterations. To maxi-
mize the observed changes, we selected five patients'
samples from our bio-bank on the basis of having the
lowest serum PON1 activity and the highest serum PON1
concentration. The patients (age: 46 to 76 years; 3 men, 2
women) had an advanced liver cirrhosis and preserved
renal function. Their diagnoses were performed by
means of a complete analytical and clinical exploration
including echography to evaluate splenomegaly or portal
vein dilation, and fibrogastroscopy to detect the presence
of gastroesophageal varices. They all had ascites. The eti-
ology of their disease was alcohol abuse. Serological anal-
yses for hepatitis B, C, and human immunodeficiency
virus infections were negative. As a control group, we
accessed five healthy volunteers from among our hospital
staff (age: 25 to 51; 3 men, 2 women). Blood samples were
collected at 4°C, immediately centrifuged, and the serum
or plasma frozen at -80°C for batched analyses. For some
of the Western blot analyses described in the Results sec-
tion we obtained liver biopsy material from 2 patients
with hepatic steatosis and inflammation, who had under-
gone bariatric surgery for the treatment of morbid obe-
sity. The study was approved by the Ethics Committee of
the Hospital Universitari de Sant Joan and written
informed consent was obtained from all the participants.
Induction of experimental liver damage in rats
To investigate the differential expression of PON1 protein
in normal and diseased livers, we employed the model of
CCl4-induced hepatic damage in rats [26]. Liver fibrosis
was induced in male Wistar rats weighing 207 ± 9 g (Pan-
lab, Barcelona, Spain) by twice-a-week intra-peritoneal
(i.p.) injections over a period of 6, 8 and 12 weeks (2 ani-
mals for each time period) of 0.5 mL of CCl4 diluted 1:1
(v/v) in olive oil. An additional group of 2 rats receiving
only the excipient olive oil was used as a control group.
Fibrosis and cirrhosis were efficiently induced in CCl4-
administered rats, as verified by histopathology. All the
animals were fed ad libitum with standard rat chow (Har-
lan Interfauna, Barcelona, Spain). Before sacrifice, the liv-
ers were removed under anesthesia, portions were frozen
in liquid nitrogen, and stored at -80°C for subsequent
analyses. The handling of animals and the procedures
described were approved by the Ethics Committee on
Animal Experimentation of the Rovira i Virgili University.
Compositional analysis of serum lipoproteins
Human serum lipoproteins were separated by a dual
detection high-performance liquid chromatography
method (HPLC) as previously described [27,28]. In brief,
100 μl of diluted serum were applied onto two columns of
TSK gel Lipopropak XL connected in tandem and eluted
at a flow rate of 0.7 ml/min with 50 mM Tris acetate buf-
fer, pH = 8.0, containing 0.3 M sodium acetate, 0.05%Marsillach et al. Lipids in Health and Disease 2010, 9:46
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sodium azide, and 0.005% Brij-35. The TSK column
medium is composed of porous polymer matrices with a
nominal bed size of 10 μm and a pore size of 100 nm. The
matrices are expected to exclude most of chylomicrons in
the void volume. The concentrations of total cholesterol,
free cholesterol, triglycerides, and phospholipids in
serum and in the eluted fractions were measured by enzy-
matic methods (Wako Chemicals, Osaka, Japan). The
concentrations of apolipoproteins (apo) A-I, apo A-II and
apo E were determined by immunoturbidimetry (Daiichi
Pure Chemicals Co., Tokyo, Japan). Lipoprotein fraction-
ation by HPLC and the measurement of lipid and apoli-
poprotein concentrations were outsourced to Skilight
Biotech Inc. (Tokyo, Japan). The lipoprotein fractions
were then returned frozen via door-to-door express cou-
rier to Reus for the measurement of PON1 activity and
concentration. PON1 activities in serum and lipoprotein
fractions were measured as the rate of hydrolysis of
paraoxon at 410 nm and 37°C [21]. PON1 concentration
was determined by an in-house enzyme-linked immuno-
sorbent assay (ELISA) method [29].
Western blot of HDL-bound and liver PON1
HDL isolation was performed by the method of Havel et
al. [30] in a Centricon 75 ultracentrifuge (Kontron Instru-
ments Ltd., Italy) using a Kontron TFT 45.6 fixed angle
rotor. We performed a denaturing gel electrophoresis
with HDL protein load of 20 μg, or 25 μg of liver protein,
in a NuPAGE® 4-12% pre-cast gel (Invitrogen, Carlsbad,
CA, USA). Because lipids modify the electrophoretic
mobility of the proteins, HDL were previously delipidated
with methanol and diethyl ether, and resuspended in
urea. Liver homogenates were obtained as previously
described [31]. Protein transfer on to a nitrocellulose
membrane was with an iBlot™ Dry Blotting System (Invit-
rogen). PON1 Western blot was performed with antibod-
ies obtained by inoculating rabbits with the peptide
CRNHQSSYQTRLNALREVQ derived from the
sequence of mature PON1, as has been described [29,32].
The antibody was used at a 1/10000 dilution. A poly-
clonal anti-rabbit-HRP secondary antibody (Dako,
Glostrup, Denmark) was used at a dilution of 1/2000. We
used the Amersham ECL™ Advanced Western Blotting
Detection Kit (GE Healthcare, Fairfield, CT, USA) for the
chemiluminescent detection of the bands. The images
were acquired with a Versadoc Gel Imaging System (Bio-
Rad, Hercules, CA, USA).
To characterize the glycosylation status of PON1
immunoreactive bands, we incubated HDL with peptide-
N-glycosidase F (PNGase F), according to the manufac-
turer's instructions (Sigma, St. Louis, MO). This enzyme
releases asparagine-linked oligosaccharides from glyco-
proteins by hydrolyzing the amide group of the asparag-
ine side chain.
Gel electrophoresis of HDL particles
HDL particle size was estimated by non-denaturing gel
electrophoresis of the HDL fraction obtained by ultracen-
trifugation. A polyacrylamide gel (Novex® 4-20% Tris-Gly-
cine pre-cast gels; Invitrogen) was run according to the
manufacturer's indications. The bands were visualized by
Coomassie®  blue staining (Colloidal Blue Staining Kit;
Invitrogen).
Measurement of other biochemical parameters
Serum cholesteryl ester transfer protein (CETP) was ana-
lyzed by the method of Lagrost and Barter [33]. Leci-
thin:cholesterol acyl transferase (LCAT) activity was
measured by the method of Lagrost et al. [34]. Phospho-
lipid transfer protein (PLTP) was determined by the
method of Damen et al. [35]. Serum total peroxides con-
centration was analyzed by a colorimetric enzymatic
assay (Immun-Diagnostik AG, Benshein, Germany).
MCP-1 concentration in EDTA plasma was measured by
ELISA (Peprotech, London, UK). Serum type III procolla-
gen-N-peptide (P-III-P) concentration, a marker of liver
fibrogenesis, was determined by radioimmunoassay
(Orion Diagnostica OY, Espoo, Finland). Serum alanine
aminotransferase, aspartate aminotransferase, γ-glutamyl
transferase, and alkaline phosphatase activities, and albu-
min and bilirubin concentrations were measured by stan-
dard methods with reagents purchased from Beckman-
Coulter (Fullerton, CA, USA).
Statistical analysis
Curvilinear regression analyses were employed to evalu-
ate the degree of association between variables. Results
are shown as means and SD (in parenthesis). Statistical
analyses were performed with the SPSS 17.0 statistical
package (SPSS Inc., Chicago, IL. USA).
Results
Changes in liver function tests and serum lipoproteins
Relative to the control group, the patients with chronic
liver impairment had, as expected, a significant increase
in serum aminotransferases and alkaline phosphatase
activities together with a decrease in albumin, HDL-cho-
lesterol, and apo A-I concentrations. They also showed a
profound decrease in serum PON1 activity and an
increase in PON1 concentration, together with an
increase in total peroxides, MCP-1, and P-III-P concen-
trations (Table 1). There were highly significant inverse
relationships between PON1 activity and total peroxides,
MCP-1, and P-III-P (Fig. 1).
We observed significant changes in the HPLC lipopro-
tein profile in the patients with respect to the control
group (Fig. 2). Patients had significant decreases in cho-
lesterol and phospholipid concentrations in very low-
density and low-density lipoproteins (VLDL + LDL, frac-Marsillach et al. Lipids in Health and Disease 2010, 9:46
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tions 10 to 22) and in HDL (fractions 23 to 30). Free cho-
lesterol was also decreased in triglyceride-rich
lipoproteins, but not in HDL. We did not observe any sig-
nificant changes in triglyceride concentrations. Apo A-I
concentrations were markedly decreased in the patients.
The results indicated two peaks which reflect two differ-
ent HDL subpopulations with compositional differences.
The peak between fractions 25 and 28 contained apo A-II
(which was significantly decreased in the patients) and
apo E (which was significantly increased), but not PON1.
The peak between fractions 29 and 35 did not contain any
apo A-II nor apo E, but contained PON1 enzyme activity
and protein mass. PON1 activity was significantly
decreased, and PON1 concentration was significantly
increased in the patient group relative to controls.
Because changes in HPLC profile do not indicate
whether the observed changes are due to compositional
changes in HDL particles or to a reduced number of par-
Table 1: Serum liver function tests, lipid and apolipoprotein levels in control subjects and patients with liver cirrhosis.
Variable Control subjects Patients p
Albumin; g/L 41.5 (1.6) 36.6 (9.1) 0.005
Alanine aminotransferase; μkat/L 0.31 (0.08) 1.08 (0.70) 0.041
Aspartate aminotransferase; μkat/L 0.35 (0.06) 1.57 (0.99) 0.025
γ-glutamyl transferase; μkat/L 0.39 (0.27) 1.19 (1.06) 0.141
Alkaline phosphatase; μkat/L 0.79 (0.25) 5.81 (4.11) 0.026
Bilirubin; μmol/L 12.8 (1.9) 19.4 (16.1) 0.410
Total peroxides: μmol/L 93.2 (12.2) 338.8 (133.2) 0.003
Monocyte chemoattractant protein-1; ng/L 41.1 (3.4) 146.0 (54.9) 0.003
Type III procollagen-N-peptide; μg/L 2.2 (1.3) 10.2 (3.3) 0.001
Paraoxonase-1 activity; U/L 362.9 (36.6) 94.9 (11.0) < 0.001
Paraoxonase-1 concentration; mg/L 62.1 (25.5) 189.3 (48.3) 0.002
Cholesterol; mmol/L 5.26 (1.29) 4.24 (2.00) 0.366
Free cholesterol; mmol/L 1.37 (0.36) 1.48 (0.76) 0.795
Triglycerides; mmol/L 1.26 (0.19) 1.31 (0.54) 0.843
Phospholipids; mmol/L 1.38 (0.36) 1.48 (0.76) 0.795
HDL-cholesterol; mmol/L 1.80 (0.50) 1.19 (0.27) 0.044
Apolipoprotein A-I; g/L 1.41 (0.40) 0.89 (0.27) 0.050
Apolipoprotein A-II; g/L 0.31 (0.11) 0.22 (0.11) 0.234
Apolipoprotein E; mg/L 25.59 (5.37) 39.20 (24.62) 0.262
Values are expressed as means and SD (in parenthesis).
Figure 1 Relationships between serum PON1 activity, total peroxides, and MCP-1 and P-III-P concentrations.Marsillach et al. Lipids in Health and Disease 2010, 9:46
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ticles, we calculated the measured variables as ratios of
apo A-I concentrations. We observed that patients with
liver impairment had a significant increase in the HDL
phospholipids to apo A-I ratio [1.75 (0.39) vs. 1.10 (0.12);
p = 0.007] and in the PON1 mass to apo A-I ratio [227.5
(93.1) vs. 45.0 (10.1); p = 0.002]. There were no significant
differences in any of the other ratios. The phospholipids
to apo A-I ratio and the PON1 protein to apo A-I ratio
were inversely correlated with PON1 activity (Fig. 3).
Abnormal immunoreactive protein reaction against anti-
PON1 antibodies
The HDL particles from cirrhotic patients contained high
levels of a protein which reacted against anti-PON1 anti-
body and had an estimated weight of 55 kDa. This protein
was not present in the control subjects (Fig. 4A). To fur-
ther characterize this protein, we performed Western
blot analysis of the liver homogenates of biopsies
obtained from patients with hepatic steatosis, as well as
from rats with CCl4-induced hepatic impairment. We
observed that the livers from both sources, the patients
and the CCl4-administered animals, had a similar immu-
noreactive band (Fig. 4B). However, when a liver homoge-
nate from a patient with steatosis was incubated in vitro
with normal human HDL and then subjected to Western
blot analysis, we did not observe any abnormal immuno-
reactive band (Fig. 4C). Further, this protein band disap-
peared when HDL was incubated with PNGase F;
suggesting tha t it consisted of glycosylated PON1 (F ig.
4D).
Changes in HDL particle size and in enzymes related to HDL 
synthesis
We investigated the alterations in HDL particle size using
non-denaturing gel electrophoresis. Patients with chronic
liver disease had a higher degree of heterogeneity with
respect to HDL particle size than healthy volunteers (Fig.
5). Electrophoretic banding patterns indicated the pres-
ence of small (<100 kDa) HDL particles only in the
patients. HDL particles between 100 and 200 kDa were
present in the sera of all five control individuals but in
only two of the patients. On the other hand large (>300
kDa) HDL were present in all five patients, but in only
two of the control subjects. We observed a significant
increase in serum CETP and PLTP, and a decrease in
LCAT activities in patients relative to controls (Table 2).
Figure 2 Compositional analysis of serum lipoproteins in the control subjects (gray lines) and cirrhotic patients (black lines).Marsillach et al. Lipids in Health and Disease 2010, 9:46
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Discussion
The molecular bases underlying the alterations in the cir-
culating PON1 activity together with its synthesis and
secretion in chronic liver diseases are far from being
completely understood, despite these changes being of
crucial importance in the pathophysiology of chronic
liver impairment. As illustrated in the present investiga-
tion, patients with liver cirrhosis had an increased serum
concentration of total peroxides (a marker of oxidative
stress), MCP-1 (an index of inflammation), and P-III-P (a
marker of liver fibrogenesis). All these changes were
observed to be strongly associated with a decrease in
serum PON1 activity. Although a direct functional rela-
tionship between serum PON1 activity alterations,
inflammation and fibrogenesis cannot be deduced from
the present investigations, these data provide further sup-
port for studies showing that oxidative stress activates
hepatic stellate cell and macrophages in vitro and in
experimental models of liver impairment [32,36-38]. A
p o s s i b l e  a n s w e r  t o  t h e  q u e s t i o n  o f  w h y  s e r u m  P O N 1
activity is decreased is that PON1 is inactivated by oxi-
dized lipids, as was shown by Aviram et al. [39] who dem-
onstrated that the incubation of PON1 in vitro with
oxidized palmitoyl arachidonoyl phosphatidylcholine,
lysophosphatidylcholine, oxidized cholesteryl arachido-
nate and oxidized LDL resulted in inactivation of PON1
arylesterase activity. Indeed, in a previous study, we
observed that alcoholic patients with a normal, or with
minimally-affected liver function, already had a
decreased serum PON1 activity that was associated with
an increase in the circulating concentration of malondial-
dehyde [23]. These data support the hypothesis of a direct
inhibition by lipid peroxides on the PON1 enzyme active
site. However, liver cirrhosis is a chronic and diffuse dis-
ease that is usually protracted in its development, and in
which multiple metabolic derangements appear progres-
sively, including an altered capacity of pan-protein syn-
thesis by the liver. A likely possibility (and one which does
not exclude an inhibition by lipid peroxidation products)
is that, in advanced liver impairment, changes in HDL
structure and composition influence PON1 activity. This
appears feasible since it is well documented that PON1
activity is profoundly dependent on the lipid and protein
compositional environment of the HDL particles [40].
Results from the present study suggest that PON1
activity and mass are associated, both in control subjects
as well as in cirrhotic patients, with a specific sub-popula-
tion of HDL particles containing apo A-I, but with not
apo A-II and apo E. These results agree with a study by
Cabana et al. [41] that showed a similar distribution of
PON1 in human HDL sub-fractions obtained by FPLC
and with experimental studies in apo A-II transgenic
mice in which apo A-II enrichment was found to displace
PON1 from HDL and, as well, to impair the antioxidant
and athero-protective function of this particle [42,43].
However, our results differ from other reports in which
HDL was isolated by other methods. Bergmeier et al. [44]
observed a high PON1 activity in HDL3 particles isolated
by ultracentrifugation, and which contained apo E.
Moren et al. [45] observed considerable PON1 activity in
apo A-II-containing HDL isolated by immunoprecipita-
tion. Methodological differences probably account for the
observed discrepancies, but we believe that HPLC or
FPLC fractionation methods are less physico-chemically
aggressive and, as such, are less likely to alter HDL com-
position in the process of isolation.
Non-denaturing gel electrophoresis showed a consider-
able increase in very small and very large HDL particles
from cirrhotic patients compared to the control subjects.
These changes are probably secondary to alterations in
Figure 3 Relationships between PON1 activity and concentration, and phospholipids in HDL particles. In calculating the ratios, the values of 
the measured variables in HPLC fractions 29 to 35 were summed and divided by the sum of apo A-I values in the same fractions.Marsillach et al. Lipids in Health and Disease 2010, 9:46
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CETP, PLTP, and LCAT levels in these patients. Although
reduced LCAT activity is common in a variety of liver dis-
eases [46], the current report is, to the best of our knowl-
edge, the first to identify increased CETP and PLTP
activities as being associated with chronic liver impair-
ment. These findings will require confirmation in much
larger studies of cases versus controls. The mechanisms
leading to increased CETP and PLTP activities in chronic
liver disease are also unclear at present. The outcome
observed could be due to increased synthesis and secre-
tion, decreased degradation (or both) or an entirely dif-
ferent mechanism such as an effect of HDL composition
on enzyme activity. Again, further studies are required.
The combination of decreased LCAT and increased
Figure 4 (A) Western blot analysis of HDL particles in control subjects and patients with liver cirrhosis. HDL from the patients had an immu-
noreactive band (very light in the case #3) of about 55 kDa. (B) Western blot analysis of liver homogenates from control rats, CCl4-administered rats 
over a period of 6, 8 and 12 weeks, and liver biopsy samples from human patients with liver steatosis. A band at the relative molecular weight of 55 
kDa increased progressively over the time-course of CCl4 administration. A similar, very intense band was observed in patients with steatosis. (C) West-
ern blot analysis of HDL particles from a control subject (CS), a patient with cirrhosis (P), and normal HDL incubated in vitro with a liver homogenate 
from a patient with steatosis. (D) Western blot analysis of HDL particles from a patient with liver cirrhosis, with and without pre-incubated with PNGase 
F.Marsillach et al. Lipids in Health and Disease 2010, 9:46
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CETP activities in the patients probably resulted in the
increase in small HDL particles. However, the greater
PLTP activity would also have resulted in increased fus-
ing of small HDL into the larger HDL particles found in
the patients [47-49]. Therefore changes in the activities of
the lipid transfer proteins could explain the different pat-
tern of HDL particles found in the patients. An increase
i n  P L T P  w o u l d  l e a d  t o  l a r g e r  H D L  p a r t i c l e s,  w h i l e  a n
enhancement in CETP and a decrease in LCAT would
result in smaller HDL particles with an increase in the
HDL3 sub-fraction. While the impact of a larger particle
size in relation to HDL function remains unclear, exten-
sive data from the literature show that small HDL parti-
cles lose most of their antioxidant properties, and may
become pro-oxidant and pro-inflammatory instead
[50,51]. In addition, results from the present study sug-
gest that these small particles do not carry PON1 and, as
such, would contribute to the decrease in serum PON1
activity observed. However, it is also possible that
changes in HDL size are associated with firmer binding of
PON1 but not with changes in activity.
We noted an inverse relationship between phospholipid
content and PON1 activity in HDL particles. In addition,
considerable amounts of PON1 protein, but low enzyme
activity, were observed in particles eluting at HPLC frac-
tions #31-35 in which phospholipids concentrations were
below the detection limit of the assay. These results sug-
gest that an appropriate balance between phospholipids
and PON1 is important in maintaining the enzyme's
activity. Indeed, the proportional distribution of phos-
pholipids and apo A-I in HDL has been shown to play an
important role in PON1 secretion, stability and activity.
Sorenson et al. [52] showed that PON1 was associated
with HDL more via the binding to phospholipids than to
apo A-I. Nevertheless, apo A-I stabilized the enzyme
activity more than did phospholipids alone. These results
were confirmed by Deakin et al. [53]. Hence the hypothe-
sis follows that an increased phospholipids to apo A-I
ratio, as observed in cirrhotic patients, contributes to
PON1 instability. Previous studies from our group
[22,23,31] showed that PON1 activity in patients with
liver disease is inversely related to PON1 mass. These
results prompted us to investigate the nature of PON1
protein in patients with cirrhosis. One of the more inter-
esting findings from the present investigation has been
the identification by Western blot of an abnormal protein
that reacted against the anti-PON1 antibody, had a higher
molecular weight than PON1, and was present in the
HDL from cirrhotic patients but not in control subjects.
This protein was also present in the livers of patients with
steatosis (a more benign form of liver disease) and in rats
with CCl4-induced cirrhosis. Additionally in these ani-
mals, the amount of abnormal PON1 increased along the
time-course of the disease development. These results
highlight the presence of this protein in liver impairment
per se, irrespective of the etiology or, even, the animal
species. The incubation of HDL with PNGase F strongly
suggests that this protein is, indeed, a highly glycosylated
form of PON1. Interestingly, Liu et al. [54] observed that
when they produced recombinant human PON1 in a bac-
ulovirus system in Hi5 insect cells, a significant propor-
tion of PON1 was synthesized as a protein of
approximately 54,000 Da, and which they identified as a
PON1 multimer. Taking these data together, we can
hypothesize that abnormal PON1 molecules are synthe-
sized under diverse altered conditions such as liver dis-
ease, or when human PON1 is synthesized by
phylogenetically-distant cells. An important finding of
the present study is that when a liver homogenate from a
patient with steatosis was incubated in vitro with normal
HDL, the altered immunoreactive band was no longer
observed. These results suggest that the high molecular
weight PON1-like protein is actively incorporated into
the HDL particles within the hepatocytes, and that it is
Figure 5 Non-denaturing electrophoresis of HDL particles.
Table 2: Serum CETP, PLTP and LCAT activities in control subjects and patients with liver cirrhosis.
Variable Control subjects Patients p
CETP; μmol/hr-·L 180.9 (27.3) 292.3 (67.1) 0.009
PLTP; mmol/hr·L 1.71 (0.27) 3.48 (1.28) 0.017
LCAT; μmol/hr·L 17.9 (2.6) 11.4 (5.3) 0.049
Values are expressed as means and SD (in parenthesis).Marsillach et al. Lipids in Health and Disease 2010, 9:46
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not a mere artifact or a result of a non-specific adsorption
of PON1 fragments by HDL particles in the circulation.
T he  pos s ibil it y e xists  t ha t  highl y glyc osyla t ed PO N1 is
abnormally assembled into HDL particles in liver disease
secondarily to alterations in protein synthesis in hepato-
cytes or to altered hepatic lipid metabolism.
Conclusions
We conclude that abnormalities in the composition of
lipids and proteins of HDL particles are associated with
the decrease in serum PON1 activity in patients with liver
disease. Of special note is the presence of a high molecu-
lar weight inactive PON1 carried in the HDL in large
quantities. These alterations may play a role in the dimin-
ished protection against oxidative stress and inflamma-
tion in these patients.
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